ITGAX and acute myeloid leukemia: Recently, it has been found that the interactions of ITGAX/ITGB2 and FCER1G could signal SYK-dependent activation of the JAK/STAT pathway in AML, and this signaling axis might serve as a novel therapeutic target for AML [33].